Ridge Bio Applies ML to Wet Lab Work on Antibody-Drug Conjugates
A Bay Area biotech is using machine learning directly in the wet lab — not just for protein prediction, but for optimizing the physical chemistry of antibody-drug conjugates.
Ridge Bio, a Bay Area biotech startup, is applying machine learning directly to wet lab processes for developing antibody-drug conjugates (ADCs), as @BiotechTV reported. Unlike the more commonly discussed applications of AI in biology — protein structure prediction, drug target identification — Ridge Bio's work focuses on optimizing the actual physical chemistry of linking cytotoxic drugs to antibodies, a notoriously finicky process that has historically relied on trial and error.
Unlock the full briefing
Get every story in today's briefing, the full archive, and the daily AI intelligence brief.
All stories today
Full archive
Daily brief
Cancel anytime. Payments powered by Stripe.